Screener
Rhythm Pharmaceuticals, Inc. RYTM Single reportable segment — Income taxes
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Global headcount expense | 58,653 | 34,868 |
| Preclinical, clinical and development expense | 18,511 | 19,960 |
| Commercial & medical affairs | 20,264 | 13,249 |
| Corporate, general & administrative | 7,888 | 7,983 |
| Other income (expense), net | (1,704) | (644) |
| Interest income (expense), net | (1,029) | (1,770) |
| Income taxes | 545 | 80 |
| Net loss | $(55,639) | $(49,498) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s single reportable segment — income taxes?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported single reportable segment — income taxes of $545K in Q1 2026.
- What does single reportable segment — income taxes mean?
- This metric represents the total tax expense accrued or paid to government authorities based on the company's taxable income. It reflects the company's tax burden and is influenced by jurisdictional tax laws and the company's overall profitability. Monitoring this is essential for understanding the net earnings available to shareholders.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s single reportable segment — income taxes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude